Phase-2 multicenter study results of Ublituximab, a novel glycoengineered antiCD20 monoclonal Antibody (mAb), in patients with Relapsing Multiple Sclerosis (RMS)

被引：0
|
作者：
Fox, E. J. [1 ]
Lovett-Racke, A. [2 ]
Inglese, M. [3 ]
Shubin, R. [4 ]
Twyman, C. [5 ]
Eubanks, J. [6 ]
Mok, K. [6 ]
Su, W. [6 ]
机构：
[1] Cent Texas Neurol Consultants, Round Rock, TX USA
[2] Ohio State Univ, Microbial Infect & Immun, Columbus, OH 43210 USA
[3] Icahn Sch Med Mt Sinai, Neurol, New York, NY 10029 USA
[4] SC3 Res Grp, Neurol, Pasadena, CA USA
[5] Associates Neurol Clin Res, Lexington, KY USA
[6] TG Therapeut Inc, Autoimmune, New York, NY USA
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2018年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
O331
引用
收藏
页码：71 / 71
页数：1
相关论文
共 50 条
  • [21] Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory CLL and MCL; Results of a Phase II Trial
    Sharman, Jeff P.
    Farber, Charles M.
    Mahadevan, Daruka
    Schreeder, Marshall T.
    Brooks, Heather D.
    Kolibaba, Kathryn S.
    Fanning, Suzanne R.
    Klein, Leonard M.
    Sportelli, Peter
    Miskin, Hari P.
    Weiss, Michael S.
    Greenwald, Daniel R.
    BLOOD, 2014, 124 (21)
  • [22] A phase I trial of ublituximab (TG-1101), a novel glycoengineered anti-CD20 monoclonal antibody (mAb) in B-cell non-Hodgkin lymphoma patients with prior exposure to rituximab.
    O'Connor, Owen A.
    Deng, Changchun
    Amengual, Jennifer Effie
    Khalil, Mazen Y.
    Schreeder, Marshall T.
    Mahadevan, Daruka
    Nikolinakos, Petros
    Sawas, Ahmed
    Zain, Jasmine M.
    Patterson, Molly
    Moon, Amber
    Pauli, Emily K.
    Cutter, Kathy
    Mackenzie, Michelle Ann
    Brotherton, Marnie
    Hodgson, Jamie
    Cooper, Christen N.
    Sportelli, Peter
    Miskin, Hari P.
    Farber, Charles Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [23] Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma; Results of a Phase II Trial
    Kolibaba, Kathryn
    Burke, John M.
    Brooks, Heather D.
    Mahadevan, Daruka
    Melear, Jason
    Farber, Charles M.
    Fanning, Suzanne R.
    Schreeder, Marshall T.
    Boccia, Ralph V.
    Sportelli, Peter
    Miskin, Hari P.
    Weiss, Michael S.
    Sharman, Jeff P.
    BLOOD, 2015, 126 (23)
  • [24] FINAL RESULTS OF A MULTICENTER PHASE IB SINGLE AGENT STUDY WITH THE NOVEL ANTI-CD20 MONOCLONAL ANTIBODY UBLITUXIMAB (TG-1101) IN PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Cazin, B.
    Lepretre, S.
    Coiffier, B.
    Aurran, T.
    Cartron, G.
    Feugier, P.
    Brehar, O.
    Sadoun, A.
    Sportelli, P.
    Miskin, H.
    Ribrag, V.
    HAEMATOLOGICA, 2013, 98 : 47 - 47
  • [25] Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
    Coiffier, B
    Haioun, C
    Ketterer, N
    Engert, A
    Tilly, H
    Ma, D
    Johnson, P
    Lister, A
    Feuring-Buske, M
    Radford, JA
    Capdeville, R
    Diehl, V
    Reyes, F
    BLOOD, 1998, 92 (06) : 1927 - 1932
  • [26] Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial
    Sharman, Jeff P.
    Farber, Charles M.
    Mahadevan, Daruka
    Schreeder, Marshall T.
    Brooks, Heather D.
    Kolibaba, Kathryn S.
    Fanning, Suzanne
    Klein, Leonard
    Greenwald, Daniel R.
    Sportelli, Peter
    Miskin, Hari P.
    Weiss, Michael S.
    Burke, John M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (03) : 412 - 420
  • [27] A phase 2 randomized, double-blinded, placebo-controlled, multicenter study of subcutaneous daclizumab, a humanized anti-CD-25 monoclonal antibody, in patients with active, relapsing forms of multiple sclerosis - Week 44 results
    Kaufman, Michael D.
    Wynn, Daniel R.
    Montalban, Xavier
    Wang, Min
    Fong, Alice
    NEUROLOGY, 2008, 70 (11) : A220 - A220
  • [28] Sustained Efficacy of Ofatumumab in Relapsing Multiple Sclerosis Patients: Results from Extended Treatment in the Phase 2 APOLITOS Study
    Saida, Takahiko
    Nakahara, Jin
    Sazonov, Denis V.
    Kurosawa, Takayoshi
    Tsumiyama, Isao
    Willi, Roman
    Zalesak, Martin
    Pingili, Ratnakar
    Haring, Dieter A.
    Ramanathan, Krishnan
    Su, Wendy
    Kira, Jun-ichi
    NEUROLOGY, 2021, 96 (15)
  • [29] A phase I dose-escalation trial of ublituximab (TG-1101), a novel anti-CD20 monoclonal antibody (mAb), for rituximab relapsed/refractory B-cell lymphoma patients
    Deng, Changchun
    Amengual, Jennifer Effie
    Schreeder, Marshall T.
    Clark-Garvey, Sean
    Patterson, Molly
    Miskin, Hari
    Sportelli, Peter
    O'Connor, Owen A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [30] A randomized, blinded, parallel-group phase-2 study exploring the efficacy, safety, and tolerability of multiple natalizumab dosing regimens in patients with relapsing multiple sclerosis (REFINE)
    Trojano, M.
    Ramio-Torrenta, L.
    Grimaldi, L. M. E.
    Lubetzki, C.
    Schippling, S.
    Evans, K.
    Gheuens, S.
    Muralidharan, K.
    Natarajan, A.
    Mikol, D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 49 - 49
12345